LivaNova (LIVN) Set to Announce Quarterly Earnings on Wednesday

LivaNova (NASDAQ:LIVN) is scheduled to be announcing its earnings results before the market opens on Wednesday, October 30th. Analysts expect the company to announce earnings of $0.71 per share for the quarter. LivaNova has set its FY 2024 guidance at 3.100-3.200 EPS and its FY24 guidance at $3.10-$3.20 EPS.Investors interested in registering for the company’s conference call can do so using this link.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, July 31st. The company reported $0.81 earnings per share for the quarter, topping the consensus estimate of $0.66 by $0.15. LivaNova had a negative net margin of 1.37% and a positive return on equity of 13.77%. The company had revenue of $318.60 million for the quarter, compared to the consensus estimate of $305.05 million. On average, analysts expect LivaNova to post $3 EPS for the current fiscal year and $3 EPS for the next fiscal year.

LivaNova Stock Performance

LIVN opened at $53.33 on Wednesday. The company has a current ratio of 3.45, a quick ratio of 2.94 and a debt-to-equity ratio of 0.49. LivaNova has a 12-month low of $42.75 and a 12-month high of $64.47. The firm has a 50 day moving average of $50.12 and a two-hundred day moving average of $53.22. The firm has a market capitalization of $2.89 billion, a PE ratio of -88.88 and a beta of 1.00.

Wall Street Analyst Weigh In

Several equities research analysts have commented on LIVN shares. Needham & Company LLC upped their price target on shares of LivaNova from $72.00 to $75.00 and gave the company a “buy” rating in a report on Wednesday, July 31st. Stifel Nicolaus upped their target price on LivaNova from $70.00 to $72.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. The Goldman Sachs Group started coverage on LivaNova in a research report on Friday, October 4th. They set a “buy” rating and a $65.00 price target for the company. Baird R W raised LivaNova from a “hold” rating to a “strong-buy” rating in a report on Tuesday, September 17th. Finally, Robert W. Baird raised shares of LivaNova from a “neutral” rating to an “outperform” rating and raised their price objective for the stock from $55.00 to $66.00 in a research note on Tuesday, September 17th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, LivaNova presently has a consensus rating of “Buy” and an average price target of $69.83.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.